estradiol + letrozole

The combination of **estradiol** and **letrozole** is a therapeutic regimen investigated for the management of vulvovaginal atrophy (VVA) in postmenopausal breast cancer patients receiving adjuvant aromatase inhibitor therapy. This combination utilizes low-dose (10 μg) intravaginal estradiol tablets (Vagifem) to provide local relief for VVA symptoms while the patient concurrently takes letrozole, a small-molecule aromatase inhibitor, to suppress systemic estrogen production for breast cancer treatment. The primary clinical concern addressed by this combination is whether local vaginal estrogen therapy causes a significant increase in systemic estradiol levels, which could potentially compromise the oncological efficacy of letrozole. Clinical trials, such as those sponsored by Helsinki University Hospital, have evaluated the safety and efficacy of this concurrent administration.

Brand names

Vagifem

Other names

estrogen + letrozolevaginal estradiol + letrozole